Recursion Pharmaceuticals (RXRX) Retained Earnings (2020 - 2026)
Recursion Pharmaceuticals' (RXRX) quarterly Retained Earnings came in at -$2.2 billion in Q1 2026, down 34.66% YoY from -$3.4 billion in Q1 2025, and down 6091.77% on a QoQ basis from $36.7 million in Q4 2025.
Recursion Pharmaceuticals (RXRX) Retained Earnings (2020 - 2026) Analysis & Trends
Recursion Pharmaceuticals (RXRX) has 7 years of Retained Earnings data on file, last reported at -$2.2 billion in Q1 2026.
- Quarterly Retained Earnings fell 34.66% year-over-year to -$2.2 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$2.2 billion (down 34.66% YoY) and the FY2025 annual result came in at $36.7 million, down 98.52% from the prior year.
- Retained Earnings retreated to -$2.2 billion in Q1 2026, from $36.7 million in the prior quarter.
- In the past five years, Retained Earnings ranged from a high of $2.5 billion in Q4 2024 to a low of -$2.2 billion in Q1 2026.
- A 5-year average of -$85.6 million and a median of -$211.0 million in 2022 frame the typical range for Retained Earnings.
- Annual changes were most pronounced in 2022 — Retained Earnings surged 893242.86% — and 2025, when it plunged 211.89%.
- Tracing RXRX's Retained Earnings over 5 years: stood at $1.1 billion in 2022, then grew by 16.64% to $1.3 billion in 2023, then jumped by 88.46% to $2.5 billion in 2024, then slumped by 98.52% to $36.7 million in 2025, then plunged by 6091.77% to -$2.2 billion in 2026.
- The last three Retained Earnings figures came in at -$2.2 billion (Q1 2026), $36.7 million (Q4 2025), and $34.1 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -4.00 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.05 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -104.13 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 4.38 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -6.33 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.57 Bn |
| 10 | Recursion Pharmaceuticals | 1.69 Bn | 1.14 Bn | -3.82 Mn | 3.21 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.21 Bn |
| Mar 31, 2026 | -2.20 Bn |
| Dec 31, 2025 | 36.72 Mn |
| Sep 30, 2025 | 34.09 Mn |
| Jun 30, 2025 | 43.62 Mn |
| Mar 31, 2025 | -1.63 Bn |
| Dec 31, 2024 | 2.47 Bn |
| Sep 30, 2024 | -1.30 Bn |
| Jun 30, 2024 | -1.16 Bn |
| Mar 31, 2024 | 1.46 Bn |
| Sep 30, 2023 | 1.31 Bn |
| Jun 30, 2023 | -781.60 Mn |
| Mar 31, 2023 | -704.90 Mn |
| Dec 31, 2022 | 1.13 Bn |
| Sep 30, 2022 | -582.10 Mn |
| Jun 30, 2022 | 959.39 Mn |
| Mar 31, 2022 | -456.06 Mn |
| Dec 31, 2021 | -126,000.00 |
| Sep 30, 2021 | -335.10 Mn |
| Jun 30, 2021 | -287.70 Mn |